COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

被引:0
|
作者
Emma Bell
Frida Ponthan
Claire Whitworth
Deborah A. Tweddle
John Lunec
Christopher P. F. Redfern
机构
[1] Newcastle University,Northern Institute for Cancer Research
[2] German Cancer Center,Division of Neuroblastoma Genomics (B087)
来源
关键词
Neuroblastoma; Cyclooxygenase; COX2; Arachidonic acid; Celecoxib;
D O I
暂无
中图分类号
学科分类号
摘要
COX2 is an inducible cyclooxygenase implicated in the metastasis and migration of tumour cells. In neuroblastoma, COX2 expression has been detected in both cell lines and tumours. The treatment of neuroblastoma cells in vitro with celecoxib, a COX2 inhibitor, induces apoptosis. The aim of this study was to investigate the role of COX2 in neuroblastoma tumour biology by creating a cell line in which COX2 could be conditionally expressed. Xenograft studies showed that the conditional expression of COX2 enhanced tumour growth and malignancy. Elevated COX2 expression enhanced the proliferation and migration of neuroblastoma cells in vitro. However, elevated COX2 expression or variation between cell lines did not affect sensitivity to the COX2 inhibitor celecoxib, indicating that celecoxib does not promote cell death through COX2 inhibition. These data show that increased COX2 expression alone can enhance the tumorigenic properties of neuroblastoma cells; however, high levels of COX2 may not be a valid biomarker of sensitivity to non-steroidal anti-inflammatory drugs such as celecoxib.
引用
收藏
页码:651 / 659
页数:8
相关论文
共 50 条
  • [21] Radiosensitization with a COX2 inhibitor with chemoradiation for head and neck cancer
    Jebasingh, J.
    Balaji, B.
    Kirushnakumar, K. S.
    Amarnath, B.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 341 - 341
  • [22] Oestrogen activates COX2 pathway
    Melanie Brazil
    [J]. Nature Reviews Drug Discovery, 2005, 4 : 16 - 16
  • [23] Characteristics of COX2 inhibitors questioned
    Petit-Zeman, S
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (09) : 726 - 727
  • [24] A COX2 molecular phylogeny of the peronosporomycetes
    Hudspeth, DSS
    Nadler, SA
    Hudspeth, MES
    [J]. MYCOLOGIA, 2000, 92 (04) : 674 - 684
  • [25] New clues in the COX2 mystery
    Peter Kirkpatrick
    [J]. Nature Reviews Drug Discovery, 2006, 5 : 4571 - 4571
  • [26] COX2 inhibition with celecoxib improves mitochondrial density in diabetic rat muscle
    Kang, S.
    Kim, H.
    Moon, J.
    Kim, H.
    Lee, B.
    Kang, E.
    Lee, H.
    Cha, B.
    [J]. DIABETOLOGIA, 2011, 54 : S222 - S222
  • [27] COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients
    De Cremoux, Patricia
    Hamy, Anne-Sophie
    Lehmann-Che, Jacqueline
    Scott, Veronique
    Sigal, Brigitte
    Mathieu, Marie-Christine
    Bertheau, Philippe
    Guinebretiere, Jean Marc
    Pierga, Jean Yves
    Giacchetti, Sylvie
    Brain, Etienne
    Marty, Michel
    Asselain, Bernard
    Spyratos, Frederique
    Bieche, Ivan
    [J]. ANTICANCER RESEARCH, 2018, 38 (03) : 1485 - 1490
  • [28] HER2 and COX2 expression in human prostate cancer
    Edwards, J
    Mukherjee, R
    Munro, AF
    Wells, AC
    Almushatat, A
    Bartlett, JMS
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (01) : 50 - 55
  • [29] COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
    Yasunori Akutsu
    Naoyuki Hanari
    Gulbostan Yusup
    Aki Komatsu-Akimoto
    Norimasa Ikeda
    Mikito Mori
    Yasuo Yoneyama
    Satoshi Endo
    Yukimasa Miyazawa
    Hisahiro Matsubara
    [J]. Annals of Surgical Oncology, 2011, 18 : 2946 - 2951
  • [30] COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
    Akutsu, Yasunori
    Hanari, Naoyuki
    Yusup, Gulbostan
    Komatsu-Akimoto, Aki
    Ikeda, Norimasa
    Mori, Mikito
    Yoneyama, Yasuo
    Endo, Satoshi
    Miyazawa, Yukimasa
    Matsubara, Hisahiro
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (10) : 2946 - 2951